Skip to main content
Uncategorized

Oryzon awarded a $300,000 research grant to accelerate development of novel therapeutics for Alzheimer’s disease

By 11 de January de 2011November 18th, 2020No Comments
< Back to news
 11.01.2011

Oryzon awarded a $300,000 research grant to accelerate development of novel therapeutics for Alzheimer’s disease

The Alzheimer's Drug Discovery Foundation (ADDF) has awarded a $300,000 grant to the Spanish biotechnology company Oryzon, for its program investigating new therapeutic approaches for Alzheimer's disease. Oryzon was founded in 2000 as a spin-off of the University of Barcelona and CSIC, and was an incubated company in the Parc Cientific Barcelona

Oryzon’s approach targets a protein discovered recently called LSD1. This protein plays a role in regulating the expression of crucial genes that neurons need to keep alive. LSD1 is able to switch the expression of those genes on and off in the neurons in response to age, insults and environmental conditions. LSD1 also regulates the expression of genes involved in the progression of Alzheimer’s disease (AD) and other neurological disorders, such as Parkinson’s and Huntington’s diseases.

The ADDF award will fund work to further optimize Oryzon’s lead molecules into future clinical candidates and to achieve proof-of-concept in regards to selectivity for LSD1 in several AD mouse models.

Oryzon was founded in 2000 as a spin-off of the University of Barcelona and CSIC and took part in the Bioincubator of the Barcelona Science Park. Today, with an international interdisciplinary team of 70 employees, the Company is recognized as the leading biomarker discovery company in Spain. Oryzon has a complementary diagnostic and therapeutic pipeline focusing on oncology and neurodegenerative disorders.